Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.
Official title: A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2023-09-21
Completion Date
2024-07-29
Last Updated
2026-07-17
Healthy Volunteers
No
Conditions
Interventions
LY3502970
Administered orally.
Placebo
Administered orally.
Locations (3)
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
Shanghai General Hospital
Shanghai, Songjiang, China